Kentucky police push for Rx-only PSE
This article was originally published in The Tan Sheet
Members of the Kentucky Narcotic Officers' Association lobby for a state law to limit sales of pseudoephedrine-containing products to prescription-only to curb the growth of methamphetamine labs. In the association newsletter, President Stanley Salyards, a Louisville Metro Police sergeant, says the federal Combat Methamphtamine Act is not working, pointing to national statistics showing the number of meth labs has been on the rise since 2006. In Kentucky, the number of labs grew 55 percent in 2008 and 2009. KNOA says Oregon's 2005 decision to make PSE available prescription-only has paid off, with a "dramatic" decrease in the number of labs there. The Consumer Healthcare Products Association hopes to dissuade states from the Rx-only route by operating an electronic system for states to track sales (1"The Tan Sheet" Oct. 26, 2009)
You may also be interested in...
Drug firms hope to dissuade states from moving drugs that contain methamphetamine precursors to prescription status by funding electronic systems to track nonprescription sales of the products
In December 2022, Nimbus Inc. completed one of the largest single-asset deals in the history of biotech, selling their TYK2 inhibitor program NDI-034858 for an up-front payment of $4bn and up to $2bn in additional milestone payments. What was it like to close a deal of that magnitude? What’s next for Nimbus? The company‘s CEO, Jeb Keiper, reflected on these questions in a recent interview with In Vivo.
Vaccines and new antibody drugs are set to transform the respiratory syncytial virus space but for now, the Swedish rare disease specialist’s 25-year old offering Synagis is enjoying increased demand.